Promising effect of rapamycin on multiple sclerosis.

Area of Science:

• Neuroimmunology
• Clinical Therapeutics
• Molecular Medicine

Background:

• Standard disease-modifying medications for relapsing-remitting multiple sclerosis (RRMS) are not universally effective.
• There is a need for novel therapeutic strategies to manage RRMS.
• Regulatory T cells (Tregs) play a crucial role in immune regulation and have been implicated in MS pathogenesis.

Purpose of the Study:

• To evaluate the efficacy of rapamycin in patients with RRMS.
• To assess the impact of rapamycin on clinical and radiological outcomes.
• To investigate the effects of rapamycin on Treg proliferation and FOXP3/GARP gene expression.

Main Methods:

• A clinical trial involving eight RRMS patients treated with rapamycin for six months.
• Brain MRI scans were performed before and after treatment to assess lesion size.
• Expanded Disability Status Scale (EDSS), Treg cell proliferation, and FOXP3/GARP gene expression were evaluated.

Main Results:

• Significant reduction in mean, minimum, and maximum plaque area size observed post-rapamycin therapy (P=0.012).
• A decrease in EDSS was noted in 50% of patients, though not statistically significant (P=0.059).
• Increased expression of FOXP3 (P=0.003) and GARP genes in Tregs was observed after treatment.

Conclusions:

• Rapamycin demonstrated a promising therapeutic response in RRMS patients.
• The drug led to significant radiological improvements and modulated key immune markers.
• Rapamycin may represent a viable therapeutic option for RRMS, with minor side effects observed.